Gilead sees cell therapy sales decline in Q3

Gilead Sciences said that its cell therapy revenue dropped 11% in the third quarter, compared with a year ago, citing lower demand for its two CAR-T cell therapies, Yescarta and Tecartus.

The light quarter, with …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844